Trial Profile

A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 10 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors AstraZeneca; MedImmune

Most Recent Events

03 May 2023 Results of phase 1b assessing (n=78; between October 25, 2013, and September 17, 2019) the safety and efficacy of durvalumab plus tremelimumab in adults with Advanced non-small cell lung cancer, published in the Journal of Thoracic Oncology.
29 Oct 2019 Status changed from active, no longer recruiting to completed.
30 Jul 2019 Planned End Date changed from 24 Apr 2019 to 17 Sep 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com